CBIO Earnings — Crescent Biopharma, Inc. Common Stock Post-ER Performance | BigEarnings
CBIO — Crescent Biopharma, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$20.65
Market Cap$569.4M
P/E—
52W Range$8.72 – $27.41
Next Earnings2026-07-30
About Crescent Biopharma, Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
